Opus Genetics Earnings Call Transcripts
Fiscal Year 2026
-
Multiple gene therapy programs are advancing, with pivotal BEST1 data expected mid-year and LCA5 showing rapid, durable vision improvements. Commercial asset Ryzumvi is expanding into presbyopia, and the pipeline leverages efficient development, strong safety, and global potential.
Fiscal Year 2025
-
OPGx-LCA5 gene therapy for LCA5 showed strong safety and efficacy in both pediatric and adult participants, with vision improvements observed as early as one month and sustained up to 18 months. All pediatric patients demonstrated gains across multiple endpoints, supporting the therapy's potential for durable, meaningful impact.
-
Positive phase III results for phentolamine in presbyopia and dim light disturbances support upcoming FDA submissions. Gene therapy programs advance with new funding and regulatory designations, while financial milestones and royalties strengthen the pipeline.
Fiscal Year 2024
-
Key opinion leaders presented strong six-month safety and efficacy data for LCA5 gene therapy, including significant improvements in visual acuity, retinal sensitivity, and functional vision. Novel digital endpoints like the virtual reality-based mobility test were highlighted as scalable and patient-friendly. Next data from pediatric cohorts are expected in 2025.
-
The acquisition creates a biotech leader in gene therapies for inherited retinal diseases, expanding the pipeline to seven programs and extending the cash runway into 2026. Four clinical readouts are expected in 2025, with strong regulatory and funding support.